Racing Against Neurodegeneration: How Scientists Plan to Predict ALS and FTD Years Before the First Symptom

For decades, neurologists have faced a cruel reality: by the time patients with amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) show symptoms, irreversible brain damage has already occurred. Now, researchers are mounting an ambitious effort to change that trajectory entirely.

The University of Miami Miller School of Medicine and the University of Pennsylvania are spearheading a five-year, $26 million study funded by the National Institutes of Health to identify biomarkers capable of predicting disease onset in people carrying the C9orf72 repeat expansion—the most common inherited cause of both ALS and FTD. The C9 ALS/FTD Prevent Study will enroll participants across 13 research sites nationwide, seeking to establish the predictive infrastructure needed for future prevention trials.

Building on the SOD1 Blueprint

The study follows a proven model. Research into SOD1-related ALS, which affects approximately 2% of ALS patients, revealed that neurofilament light chain levels rise roughly one year before symptoms appear. That discovery enabled the ATLAS prevention trial using tofersen (marketed as Qalsody), demonstrating that early intervention is feasible when the right biomarkers exist.

But C9orf72 presents a more complex challenge. Unlike SOD1, no single biomarker has emerged to reliably predict when carriers will develop symptoms. Dr. Michael Benatar, who holds the Walter Bradley Chair in ALS Research at the University of Miami Miller School of Medicine, and Dr. Corey McMillan from the Penn Frontotemporal Degeneration Center at the University of Pennsylvania Perelman School of Medicine are leading the effort to identify not just one marker, but a panel of predictive indicators.

Integrating the ALS-FTD Spectrum

What makes this study particularly innovative is its integrated approach across the full disease spectrum. The research team combines expertise from neurologists, psychiatrists, and neuropsychologists to assess both motor and cognitive changes in C9orf72 carriers. This comprehensive monitoring strategy acknowledges that ALS and FTD exist on a continuum, with many patients exhibiting features of both conditions.

The primary goal is straightforward but transformative: establish enrollment criteria for prevention trials by identifying which biomarkers—or combination of biomarkers—signal impending disease onset. Success would mean that asymptomatic individuals carrying the C9orf72 mutation could receive interventions before neurological damage becomes irreversible.

Implications for Precision Medicine

The study's impact extends beyond academic research. For pharmaceutical companies developing C9orf72-targeted therapies, validated biomarker panels would provide clear patient selection criteria, potentially accelerating regulatory pathways similar to the SOD1 model. Healthcare systems will need infrastructure for longitudinal monitoring of asymptomatic genetic carriers, creating demand for integrated data platforms capable of tracking subtle changes across multiple clinical domains.

The research also opens opportunities for artificial intelligence applications in pattern recognition, as machine learning platforms may prove essential for identifying complex biomarker signatures across motor function, cognitive assessments, behavioral changes, and blood-based markers.

By shifting the intervention window to before symptoms begin, the C9 ALS/FTD Prevent Study represents a fundamental reimagining of how neurodegenerative diseases might be managed—not just treated, but potentially prevented altogether.

Sources

1. Researchers Launch $26 Million Study to Predict ALS and FTD Before Symptoms Begin — University of Miami Miller School of Medicine News